Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference
Pulmonx Corporation (LUNG)
US:NASDAQ Investor Relations:
investor.prolunginc.com/investor-relations
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Lake Street 8th Annual Best Ideas Growth Conference in New York on Thursday, September 14, 2024. About Pulmonx CorporationPulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidel
Show less
Read more
Impact Snapshot
Event Time:
LUNG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUNG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUNG alerts
High impacting Pulmonx Corporation news events
Weekly update
A roundup of the hottest topics
LUNG
News
- Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024GlobeNewswire
- Pulmonx to Present at the 2024 Wells Fargo Healthcare ConferenceGlobeNewswire
- Analysts Are Updating Their Pulmonx Corporation (NASDAQ:LUNG) Estimates After Its Second-Quarter Results [Yahoo! Finance]Yahoo! Finance
- Pulmonx Co. (NASDAQ: LUNG) had its price target raised by analysts at Canaccord Genuity Group Inc. from $15.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Pulmonx Co. (NASDAQ: LUNG) had its price target lowered by analysts at Wells Fargo & Company from $14.00 to $10.00. They now have an "equal weight" rating on the stock.MarketBeat
LUNG
Earnings
- 7/31/24 - Beat
LUNG
Sec Filings
- 9/18/24 - Form 4
- 9/12/24 - Form 144
- 9/5/24 - Form 4
- LUNG's page on the SEC website